NNC 01-0687

Last updated

NNC 01-0687
ADX-10061.svg
Clinical data
Other namesADX-10061; CEE 03-310; CEE-310; NNC 01-687; NNC-687; NO-687
Drug class Dopamine D1-like receptor antagonist
Identifiers
  • (5S)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-1,2,4,5-tetrahydro-3-benzazepin-7-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C19H20N2O4
Molar mass 340.379 g·mol−1
3D model (JSmol)
  • CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC4=C3OCC4)O)[N+](=O)[O-]
  • InChI=1S/C19H20N2O4/c1-20-7-5-13-9-17(21(23)24)18(22)10-15(13)16(11-20)14-4-2-3-12-6-8-25-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
  • Key:XZPSYCOYKJRHKE-MRXNPFEDSA-N

NNC 01-0687 (also known as ADX-10061, CEE-03-310, or NNC-687) is a selective dopamine D1-like receptor antagonist of the benzazepine group which was under development as an experimental antipsychotic for the treatment of schizophrenia but was never marketed. [1] [2] [3] Its development for schizophrenia was discontinued due to lack of effectiveness in clinical trials. [2] [4]

Subsequently, NNC 01-0687 was developed under the code name ADX-10061 for treatment of substance dependence and was studied for smoking cessation, alcohol dependence, and cocaine dependence. [3] It was also developed for treatment of sleep disorders. [1] However, development for all of these indications was also discontinued, by 2007, and the drug was never marketed for any use. [1]

NNC 01-0687 was first described in the scientific literature by 1992. [5]

See also

References

  1. 1 2 3 "ADX 10061". AdisInsight. Springer Nature Switzerland AG. 3 October 2007. Retrieved 19 October 2024.
  2. 1 2 Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (December 2012). "Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents". Molecular Psychiatry. 17 (12): 1206–1227. doi:10.1038/mp.2012.47. PMID   22584864.
  3. 1 2 Heidbreder C (1 January 2005). "Recent Advances in the Pharmacotherapeutic Management of Drug Dependence and Addiction". Current Psychiatry Reviews. 1 (1). Bentham Science Publishers Ltd.: 45–67. doi:10.2174/1573400052953538. ISSN   1573-4005.
  4. ↑ Bolós J (May 2003). "Current strategies for the development of novel antipsychotic drugs". Mini Reviews in Medicinal Chemistry. 3 (3): 239–251. doi:10.2174/1389557033488169. PMID   12570839.
  5. ↑ Christensen JV (June 1992). "Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5- tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography". Journal of Chromatography. 577 (2): 366–370. doi:10.1016/0378-4347(92)80261-n. PMID   1301070.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.